

Breast Cancer HER-2 Negative Breast Cancer

## A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
42 Countries

**Trial Identifier**  
NCT01358877  
TOC4939G,2010-022902-41,BIG  
4-11 BO25126

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT01358877 TOC4939G,2010-022902-41,BIG 4-11 BO25126**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---